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Leishmaniasis is one of the neglected diseases that remain in need for pharmacological alternatives. 
In this context, N-Myristoyltransferases (NMT) arise as interesting targets to explore since they are 
involved in the co/post-translational processing of peptides which are responsible for host cell invasion. 
Studies that consider these enzymes as targets point out the potential of benzoheterocyclic compounds as 
inhibitors of Candida albicans’s N-myristoyltransferase. Here we applied a combination of comparative 
binding site analysis and molecular docking studies based on a Piggyback approach in the search for new 
Leishmania major NMT ligands. Our results revealed that NMT enzymes from both pathogens present 
enough structural similarity to allow extrapolation of the knowledge available from C. albicans studies 
to develop new L. major NMT inhibitors. Molecular docking studies with benzoheterocyclic analogues 
indicate the potential of benzothiazole derivatives as L. major NMT ligands, giving rise to a completely 
new class of chemical compounds to be explored in the development of antileishmanial drugs.
Keywords: N-myristoyltransferase. Leishmaniasis. Benzofuran. Benzothiazole. Molecular docking. 
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INTRODUCTION
N-Myristoyltransferases (NMT) are fundamental 
enzymes to processes of addressing protein to the 
plasmatic membrane, stabilizing their structures and 
mediating protein interactions (Alvar et al., 1997; 
Bhatnagar et al., 1999; Martin, Beauchamp, Berthiaume, 
2011). They participate in the co/post-translational peptide 
processing by linking a myristic acid unit to the amino 
terminal residue of a targeted protein (Bowyer et al., 2008; 
Brannigan et al., 2010; Martin, Beauchamp, Berthiaume, 
2011).
These enzymes are present in several species 
including humans (Duronio, Reed, Gordon, 1992), fungi 
(Lodge et al., 1994; Towler et al., 1987; Wiegand et al., 
1992) and parasites (Gunaratne et al., 2000; Price et al., 
2003); are essential to the growth and survival of several 
eukaryotes, a fact that makes them interesting targets 
to explore in the search for new anti-infective therapies 
(Bowyer et al., 2008; Mills et al., 2007; Price et al., 2003; 
Resh, 2012; Tate et al., 2014).
Leishmaniasis is a set of infectious diseases 
that afflicts more than 350 million people worldwide. 
Approximately 90% of the cases occur in developing 
countries such as Bangladesh, India and Brazil, a number 
that reflects the strong rural and neglected epidemiological 
profile of this disease (PAHO, 2015; WHO, 2017). 
Leishmaniasis’s etiological agents are kinetoplastids from 
the genus Leishmania that also present NMT as one of 
their co/post-translational protein processing enzymes. 
Leishmania (Leishmania) major’s NMT, for instance, 
is an essential enzyme to the host invasion capability of 
this parasite and presents 41, 43, and 40% of sequence 
similarity with Saccharomyces cerevisae, Candida 
albicans and Plasmodium falciparum NMT enzymes, 
respectively (Maurer-Stroh et al., 2002).
Small molecules with inhibitory activity over 
these enzymes have already been reported. Benzofuran 
analogues were studied by Ebara et al., and resulted in 
excellent inhibitors of Candida albicans NMT (CaNMT), 
with minimum inhibitory concentration (MIC) values 
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around 0.1 µM (Ebara et al., 2005; Ebiike et al., 2002; 
Masubuchi et al., 2003). Yamazaki et al. have also explored 
benzothiazole structures because of their potential activity 
against CaNMT. After structural optimizations guided by 
systematic rational modifications, inhibitors with high 
affinity and selectivity were obtained (Ohtsuka , Aoki, 
2003; Yamazaki et al., 2005).
Evaluating the structures of both classes of reported 
inhibitors, at least three similar structural elements are 
noticeable: the presence of a benzoheterocyclic core 
with two main side chains, at C2 and C4/6 positions of the 
benzoheterocyclic system; a secondary amine at C4/6 side 
chain, and a hydrophobic group linked to the C2 side chain 
(Figure 1A).
More recent reports have shown the efficacy of 
benzoheterocyclic molecules in inhibiting the Plasmodium 
falciparum NMT (PfNMT) (Brannigan et al., 2010; 
Tate et al., 2014). These studies were carried out based 
on the Masubuchi et al. developments and employed 
a methodology known as Piggyback Approach (Gelb, 
2007). This methodology saves a lot of time and money 
because it repurposes a well-designed work, usually found 
ineffective for its original design, to advance quickly in 
the process of a new drug development. Frearson et al. 
also identified a series of sulfonamide analogues with 
high affinity to the Trypanosoma brucei NMT (TbNMT), 
confirming the potential of these enzymes as suitable and 
valid targets in the search for new anti-trypanosomatids 
(Frearson et al., 2010).
In the present work, we carried out a comparative 
analysis between the crystallized binding sites of LmNMT 
and CaNMT, followed by docking studies of a benzofuran 
analogue (BF), which have been reported as active against 
the CaNMT. We also suggested the docking studies of a 
benzothiazole analogue (BTZ) that resembles, as closely 
as possible, the structural features of BF, with the rationale 
of observing how such characteristics modulates a possible 
binding mode at LmNMT (Figure 1B).
This work is also based on the principles of 
Piggybacking, which is an attractive approach for 
developing therapeutic alternatives for leishmaniasis, 
a neglected disease. Moreover, LmNMT is a novel and 
poorly explored target that could provide a whole new field 
in the research for antileishmanial compounds.
MATERIAL AND METHODS
Structural comparison between the binding sites 
of CaNMT and LmNMT was carried out by employing 
crystal structures retrieved from Protein Data Bank under 
the entry codes 1iyl (3.2 Å resolution) and 3h5z (1.49 
Å resolution) for CaNMT and LmNMT respectively, as 
reference. Both enzymes were preprocessed by adding 
missing hydrogens and by removing water molecules. 
FIGURE 1 - General structure of the reported inhibitors of CaNMT (A) and the chemical structures of the specific compounds 
studied herein (B).
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Visual inspection for structural errors, mainly at the 
binding site region, was also performed, followed by 
a revision of the PDB files for significant structural 
comments, such as missing residues.
Structures were superimposed in the Maestro 10.4 
molecular visualizer to perform the visual structural 
comparison. Connolly Molecular Surfaces were 
constructed employing the Molecular Surface module 
of this software and by setting the surface resolution to 
“Medium”, the probe sphere radius of 1.4 Å and a VDW 
radius scale of 1.0.
The similarity index was calculated by employing 
ProBis Web-Server (Konc, Janežič, 2010). Both PDB 
preprocessed structures were input at the server and the 
chain A was defined as the one exhibiting the binding site. 
“Local Alignment Only” and a Z’score value “Cutoff” of 
1.0 were employed as Additional Settings to this analysis. 
BF and BTZ were sketched in the GaussView 5.0.9 
software and had their structural geometries optimized by 
first considering MM+ parameters, followed by a local 
minima conformer search up to energy differences of 0.01 
kcal/mol and considering semi empirical methods (PM3). 
The single point energy calculation was then performed 
by employing the Gaussian 09W software, with PM3 
force field.
Compounds were docked fifteen times at CaNMT 
and LmNMT enzymes using the Gold 5.4.0 software to 
generate 10 solutions each, producing a final pool of one 
hundred and fifty docked poses to be analyzed to each 
compound. A Myristoyl-CoA molecule was considered 
at the cofactor binding site throughout LmNMT docking 
studies. As reference to the binding site, it was considered 
a region of 14 Å around the terminal leucine residue 
(Leu451 at CaNMT and Leu421 at LmNMT). Moreover, 
a hydrogen bond interaction between the terminal leucines 
and the aliphatic nitrogen present in the side chain at C4 or 
C6 position of the ligands was set as constraint.
This standard protocol was established after 
redocking studies of CaNMT and its co-crystallized 
ligand, the (1-methyl-1H-imidazol-2-yl)-(3-methyl-4-{3-
[pyridine-3-ylmethyl)-amino]-propoxy}-benzofuran-2-yl)
methanone, a benzofuran analogue with chemical structure 
different from the BF test compound (Supplementary 
Information).
The redocking results were analyzed by considering 
two score functions, Goldscore and Chemscore, which 
presented the best scoring for the co-crystallized ligand, 
and three criteria of interaction that mimic the findings of 
Masubuchi et al. to benzofuran derivatives at CaNMT: a) 
distances between the aliphatic nitrogen of the side chain 
at C4 or C6 positions of the ligands and the carboxylic 
oxygen of C-terminal leucine residues (Leu451 at CaNMT 
and Leu421 at LmNMT); b) distances between the 
heteroatom that can act as a hydrogen bond acceptor in the 
heterocyclic ring and the histidine from S2 region (His227 
and His219 to CaNMT and LmNMT, respectively); c) 
orientation of the hydrophobic substituent in C2 of the 
heterocyclic systems towards the hydrophobic region S3. 
Distances lower than 4Å were considered as indicative of 
potential molecular interactions, since the crystallographic 
data from Sogabe et al. showed interactions at distances 
up to this value (Sogabe et al., 2002).
The best docked poses from docking studies were 
analyzed by employing the software Maestro (v.10.4), 
by considering the two score functions, Goldscore and 
Chemscore and by applying the aforementioned criteria 
to the redocking studies. 
RESULTS AND DISCUSSION
Superimposition of chain A from both crystals 
exhibited a similarity index of 4.21, represented in terms 
of Z-score (Probis Web-based software), a statistical 
function that represents how much an alignment differs 
from the mean obtained when considering the whole 
population of possible alignments. Z-score values above 
2 are considered highly significant (Konc et al., 2012).
Visual evaluation was also applied to compare the 
positioning of the proteins binding site residues, precisely 
in their active state. Both crystals were obtained and 
described as in their active conformations. 
Residues involved in interactions with the 
benzofuran analogue co-crystallized with CaNMT from 
the Masubuchi et al. (2003) studies were considered as 
a reference to determine the binding site of LmNMT 
(Ebara et al., 2005; Ebiike et al., 2002; Masubuchi et al., 
2003). According to their findings, the binding residues are 
organized to produce three major pockets: S1, S2 and S3 
(Figure 2A). A similar positioning of equivalent residues 
at LmNMT produces the same three major sites, but with 
some significant differences (Figure 2B).
S1 configures the catalytic region with the C-terminal 
leucine (Leu451 at CaNMT and Leu421 at LmNMT) 
playing a crucial role in the transfer of the Myristoyl-CoA 
subunit to the substrates. As it may be noted, this region 
is much larger in the CaNMT than in the LmNMT. This 
seems to be explained mostly by the fact that the equivalent 
tyrosine residues, Tyr119 and Tyr92, take a different steric 
positioning, with the aromatic ring of the Tyr92 occupying 
the space between the Leu421 and the Phe90. The same 
region at CaNMT is located between Leu451 and Phe117 
and is not filled by any residue. Additionally, the aromatic 
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ring of the Tyr119 is positioned 90 degrees to the aromatic 
ring of Tyr107 which could indicate a potential Pi-stacking 
interaction with this residue.
S2 region, in turn, revealed to be the most preserved 
region between the two enzymes, with the histidine 
residues (His227/219, CaNMT/LmNMT) occupying 
the same position in both crystals. Masubuchi et al. 
reported this histidine as one of the main interaction 
points, specifically interacting with the heteroatom of the 
benzoheterocycle (Masubuchi et al., 2003).
The main differences observed between the two 
crystals were, however, at S3 region. This region of CaNMT 
is composed by three phenylalanine residues, Phe115, 
Phe240, Phe339, generating a tight hydrophobic cavity. 
The same region at LmNMT presented a replacement of 
one of the phenylalanine residues (Phe339) for a serine, 
the Ser330, a polar amino acid that promotes, accordingly, 
a little increase in the polarity of this cavity at LmNMT. 
Moreover, this pocket was slightly larger than its equivalent 
at CaNMT, a fact that could also be explained by the smaller 
size of the Ser330 residue when compared to the Phe339.
Intriguingly, the residues Phe90 and Tyr345, while in 
this crystallized active conformation of LmNMT, generate 
a steric salience between S1 and S3 pockets that could 
interfere with the accommodation of more hindered or 
rigid ligands.
This comparative analysis of the crystallized 
active conformation of both enzymes was a useful guide 
to comprehend the differences between the two test 
compounds in the docking results.
Docking results of BF at CaNMT binding site 
reproduced the findings of Masubuchi et al. in 81% of the 
obtained docking poses. Scores of 87.830 (Goldscore) and 
43.796 (Chemscore) were obtained to the best pose. This 
result validates our theoretical docking protocol, since 
BF exhibited excellent in vitro activity against CaNMT 
(Kawasaki et al., 2003). Hydrogen bonds (H-bonds) can be 
observed between the benzofuran oxygen and the His227 
as well as between the nitrogen from 2-piridinyl ring at 
C4 side chain and the Tyr119. Some poses have shown 
H-bonds occurring between the His227 and the oxygen 
from the C2 chain side instead of the benzofuran oxygen, 
but this possibility was also observed by Masubuchi et al. 
(2003) (Figure 3A).
Pi-stacking interactions were established at 
both extremities of the molecule. The 2-pyridinyl ring 
interacts with Phe117 as well as the trifluorobenzene, at 
C2 side chain, interacts both with Phe115 and Phe240. 
These results reinforce the importance of hydrophobic 
interactions at S3 pocket to the recognition by the CaNMT.
The BTZ docking at CaNMT, however, did not show 
the same profile. Only 55% of the 150 solutions met the 
established criteria of analysis and resembled the reference 
pose described by Masubuchi et al. Score values of 77.259 
(Goldscore) and 34.412 (Chemscore) were obtained. 
When compared to BF, these results could indicate that 
BTZ might not be such a good ligand of CaNMT as BF. 
The best pose, however, exhibited the same 
previously described crucial interaction points to good 
ligands (Figure 3B). H-bonds were observed between the 
FIGURE 2 - Comparison between the binding sites of CaNMT (A), the reference enzyme, and LmNMT (B).
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nitrogen from C4 side chain and the Leu421 as well as 
between the benzothiazole nitrogen and His227. Possible 
H-bonds with the oxygen from the C2 side chain and this 
histidine were also observed to the BTZ. Similarly, pi-
stacking interactions with the phenylalanine residues from 
S3 pockets were visualized, but no such interaction was 
observed at C4 side chain.
Although Yamazaki et  al .  had synthesized 
benzothiazole analogues with excellent CaNMT inhibitory 
activity, none of them resembles the structure of BTZ 
herein studied. In fact, their best compounds present large 
groups at C6 side chain of the benzothiazole system, which 
could possibly result from a better adjustment of them at 
S1 site of C. albicans enzyme. Our comparative analysis 
has revealed this site larger than the one from LmNMT 
and, consequently, their biological findings corroborate 
ours (Yamazaki et al., 2005).
Regarding the LmNMT, molecular docking studies 
pointed out BTZ as a better ligand of this enzyme than its 
benzofuran analogue BF.
The reference pose was observed for the BF in only 
30% of the solutions (Figure 4A) with score values of 
61.794 (Goldscore) and 27.438 (Chemscore). The best 
pose presented, however, H-bond interactions in three 
distinct points: between the nitrogen from the C6 side 
chain of BF and both Leu421 carboxylic oxygens as well 
as with the Tyr92 aromatic hydroxy group. Nitrogen from 
the 2-pyridinyl group has also established H-bond with the 
Tyr80. Pi-stacking interactions could be observed not only 
between the aromatic ring from C2 side chain and Phe232 
but also between the benzofuran ring and Phe90. 
Neither the oxygen of the benzofuran ring nor the 
oxygen of C2 side chain positioned itself close enough to 
established H-bonds with the His219. The closest distance 
achieved between these ligand groups and the enzyme is 
shown at Figure 4A and was of 3.15 Å. 
Despite this suitable pattern of interactions, bad 
steric contacts can be easily detected. The methyl group at 
C3 position of benzofuran system, for instance, is found in 
an unsuitable proximity of Tyr345 and Asn376. A similar 
situation is observed with the positioning of the C4 side 
chain carbons, which seem to assume a hard angle to 
fit into the S1 cavity. The steric salience formed by the 
residues Phe90 and Tyr345 at LmNMT could explain why 
BF assumed such a bad positioning, since this salience 
could be incompatible with BF’s more rigid and hindered 
(by the methyl C3 group) structure.
Our findings to BF are, thus, conflicting since the 
compound showed some poses with relevant score values 
associated to a suitable pattern of interactions. The low 
incidence of similar docked poses, however, could induce 
one to conclude that BF might not be a good ligand of 
LmNMT. The complex, however, could assume a more 
relaxed positioning when considering the dynamics of 
the system. For this reason, BF could not be neglected as 
a potential ligand of LmNMT. 
BTZ, on the contrary, exhibited a high frequency of 
repeated poses, 80%, similar to the reference, with higher 
score function values, 74.453 (Goldscore) and 20.842 
(Chemscore). 
FIGURE 3 - Docking studies with CaNMT. A. BF best docked pose; B. BTF best docked pose. Dotted lines represent the observed 
interactions. Yellow: H-bonds; Blue: Pi-stacking interactions; Magenta: potential H-bonds.
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The nitrogen from the C6 side chain positioned itself 
close enough from the Leu421 to establish H-bonds with 
both carboxylate oxygens. His219 also interacts through 
H-bonds with the oxygen from the C2 side chain. The 
nitrogen from benzothiazole ring is also close enough 
from the His219 to establish such interaction and, half of 
the best docked poses showed this interaction, instead of 
with the oxygen from C2 side chain, as the most probable 
one (Figure 4B).
Finally, a fourth possible H-bond interaction could 
be observed, occurring between the Tyr345 and the oxygen 
from the C6 side chain (Figure 4C). 
These findings agree with what other authors 
observed. 
Yu et al. (2012) also employing the Piggyback 
approach, identified a benzofuran analogue which could 
be recognized by the Plasmodium falciparum NMT 
(PfNMT). They synthesized a benzofuran structure very 
similar to that studied by Masubushi et al. and submitted 
it to crystallography analysis. Their results showed a 
ligand positioning very similar to the one observed in this 
study, with the oxygen of the benzofuran ring establishing 
H-bond interactions with the His213, the equivalent 
residue of the His219 from LmNMT. They also observed 
H-bonds between the His213 and the oxygen atom from 
the ester carbonyl group at C2 of their benzofuran core. 
This oxygen occupies a similar positioning in this ligand to 
the one at C2 from the BTZ herein studied (Yu et al.,2012).
FIGURE 4 - Docking studies with LmNMT. A. BF best docked pose; B. BTF best docked pose, view 1; C. BTF best docked pose, 
view 2. Dotted lines represent the observed interactions. Yellow: H-bonds; Blue: Pi-stacking interactions; Magenta: potential 
H-bonds.
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H-bond interactions with the terminal leucine 
residues and the neighbor tyrosine, in PfNMT Leu410 and 
Tyr107, were also observed both with the nitrogen from 
the 2-pyridinyl ring from C4 side chain. In the case of 
BTZ-LmNMT complex, however, these interactions were 
established by different atoms of the ligand, as already 
described.
In fact, several studies with NMT both from P. 
falciparum and P. vivax show these two residues as 
important in the recognition of ligands by the active site 
of these enzymes (Goncalves et al., 2012; Yu et al. 2012; 
Rackham et al., 2013; Rackham et al., 2014).
BTZ presented good steric complementarity to 
LmNMT, with the trifluorobenzene ring at C2 side chain 
pointed toward the most hydrophobic region of S3 
cavity; however no Pi-stacking interaction was observed 
between this ring and the phenylalanine residues. Pi-
stacking interactions, however, depend on the positioning 
of planar rings which, in turn, rotate freely. This means 
that, when considering the dynamics of the system, the 
trifluorobenzene ring can assume the right positioning 
to establish pi-stacking with the Phe88 and Phe232, as 
observed in the case of BF.
Previous homology and docking studies followed by 
molecular dynamics simulations revealed the topology of 
the binding sites from different parasitic NMTs, including 
the LmNMT. The authors described five important regions: 
two hydrophobic pockets, a hydrogen bonding pocket and 
two other pockets which also establish hydrogen bonding 
interactions, but one is negatively-charged while the other 
is positively-charged. Among the residues constituting one 
of the hydrophobic pockets in LmNMT model, the Phe88, 
Phe90, Phe232 were mentioned (Sheng et al., 2009). 
The positioning of BTZ trifluorobenzene ring 
towards theses residues could be explained by the 
tendency of this moiety in interacting through hydrophobic 
forces in this region.
Moreover, the higher number of H-bonds established 
within BTZ-LmNMT, allied to the higher incidence of 
similar poses, configures BTZ as a potentially better 
ligand of this enzyme than BF and, consequently, a good 
prototype to optimize in searching for new antileishmanial 
agents.
CONCLUSION
In conclusion, our results indicate that CaNMT and 
LmNMT are very similar in their residues arrangement 
of S1, S2 and S3 regions from the binding site, allowing 
to extrapolate the knowledge of CaNMT inhibitors to the 
development of new anti-LmNMT compounds. 
BTZ was indicated as a good prototype to be 
optimized in the search for new inhibitors, while BF 
presented inconclusive results. 
Due to the protrusion observed in the structure of 
LmNMT, less hindered and/or flexible ligands could 
present better docking behavior when regarding this 
enzyme, but studies of molecular dynamics could shed 
some light on this aspect. 
Dynamics simulations might also improve the 
comprehension of aspects not observable through 
molecular docking studies, such as factors related to the 
essential induced fit phenomenon. For these reasons, such 
studies have already been initiated to the complexes herein 
discussed, particularly to BTZ-LmNMT.
BTZ presented good score functions values 
associated with interaction with residues previously 
reported as important to inhibitors recognition, such as 
with the His219, Leu421 and a predisposition to direct its 
most hydrophobic ring, the trifluorobenzene ring at C2 side 
chain, toward the hydrophobic S3 region.
Finally, BF exhibited a suitable profile of molecular 
interactions with LmNMT, but only at 30% of the docking 
results. The compound, however, should not be discarded 
as a potential ligand of this enzyme since the same 
induced fit phenomena could help in ligand adjustment 
to the enzyme recognition site. Further studies should 
be performed to better understand the BF potential as a 
LmNMT inhibitor.
In general, the results herein discussed are in 
agreement with previously reported findings described to 
experimentally proved NMT inhibitors. This supports the 
potential of this benzoheterocyclic analogues as potential 
NMT inhibitors which might be explored in searching for 
new antileishmanial compounds.
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